BioMedTracker is featuring content from respected outside sources to augment its original report content. This article was originally published by START-UP, April 2015. START-UP provides in-depth profiles of leading-edge companies and technologies, including the most important new trends in the biopharma, medtech and diagnostics industries. Data in the article comes from Strategic Transactions and Medtrack.

For more information about START-UP, please visit START-UP here. For more information about Strategic Transactions, please visit Strategic Transactions here. For more information about Medtrack, please visit Medtrack here.

Based on a five-year analysis of the biopharma investments of SR One, Novartis Venture Funds, and Johnson & Johnson Development Corp., the "parent" entities of these CVC arms rarely, if ever, forge partnerships with their biotech portfolios.

For our disclosures, please read the BioMedTracker Research Standards.